Roche Holding AG

Roche’s oral SERD giredestrant shows a landmark IDFS benefit in early ER‑positive breast cancer, potentially redefining standard care and boosting patient outcomes.

Roche Holding AG has made significant strategic expansions in both its metabolic and diagnostic segments through the acquisition of 89bio and the certification of its Ionify 25-Hydroxy Vitamin D Test, solidifying its position as a leader in the heal…